Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cadrenal Therapeutics, Inc. - Common Stock (NQ:CVKD)

8.567 +0.317 (+3.84%)
Streaming Delayed Price Updated: 9:55 AM EST, Dec 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cadrenal Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Cadrenal's Quiet Expansion Play Is Starting to Get Loud
Via ACCESS Newswire
News headline image
Cadrenal's Anticoagulation Platform Is Expanding in a $40 Billion Market
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
Cadrenal Therapeutics Expands Pipeline With Portfolio Acquisition Worth Up To $15 Million ↗
Via Stocktwits
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Cadrenal Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
From Cadrenal Therapeutics, Inc.
Via Business Wire
News headline image
Cadrenal Therapeutics Announces Clinical Trial Initiation Plans for Tecarfarin in Patients with End-Stage Kidney Disease (ESKD) Transitioning to Dialysis
From Cadrenal Therapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients
From Cadrenal Therapeutics, Inc.
Via Business Wire
News headline image
Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025
From Cadrenal Therapeutics, Inc.
Via Business Wire
News headline image
Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness
From Cadrenal Therapeutics, Inc.
Via Business Wire
News headline image
$34 Billion Market in 2025 Advancing to $45 Billion in 2026 for Phase III Development of New Blood Thiner, Less Problematic Than Warfrain: Cadrenal Therapeutics, Inc. (Nasdaq: CVKD)
Via Get News
Topics Death Economy
News headline image
Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update
From Cadrenal Therapeutics, Inc.
Via Business Wire
News headline image
Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences
From Cadrenal Therapeutics, Inc.
Via Business Wire
News headline image
Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin
From Cadrenal Therapeutics, Inc.
Via Business Wire
News headline image
Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD
From Cadrenal Therapeutics, Inc.
Via Business Wire
News headline image
Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin
From Cadrenal Therapeutics, Inc.
Via Business Wire
News headline image
Cadrenal Therapeutics to Present at BIO CEO & Investor Conference
From Cadrenal Therapeutics, Inc.
Via Business Wire
News headline image
Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
From Cadrenal Therapeutics, Inc.
Via Business Wire
News headline image
Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications
From Cadrenal Therapeutics
Via Business Wire
News headline image
Cadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings
From Cadrenal Therapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Champions Oncology Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Sidoti Events, LLC's Virtual August Micro-Cap Conference
Via ACCESSWIRE
News headline image
CVKD Stock Earnings: Cadrenal Therapeutics Misses EPS for Q2 2024 ↗
CVKD stock results show that Cadrenal Therapeutics missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
CVKD Stock Earnings: Cadrenal Therapeutics Misses EPS for Q1 2024 ↗
CVKD stock results show that Cadrenal Therapeutics missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗
We're starting off Thursday with a breakdown of all the biggest pre-market stock movers traders will want to keep an eye on this morning! 
Via InvestorPlace
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.